NL-OMON46900已完成2 期
Activity of trastuzumab based chemotherapy in metastatic breast cancer patients with HER2-negative primary tumor but HER2 positive circulating tumor cells - CareMore-Trastuzumab
Interne Oncologie0 个研究点目标入组 9 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
Trial ended prematurely
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Female patient with metastatic breast cancer with HER2-negative primary tumor
- •Age >= 18 years old
- •WHO performance status <=2
- •Considered fit enough to receive trastuzumab/taxane-based chemotherapy by the treating physician
- •Able to understand and give written informed consent;Secondary inclusion criteria:
- •Female patient with metastatic breast cancer with HER2-negative primary tumors with the presence of at least one HER2-positive CTC
- •Adequate left-ventricular ejection fraction (LVEF) of at least 45%
排除标准
- •Previous chemotherapy for metastatic disease.
- •Adjuvant chemotherapy within 6 months prior to treatment start.
- •Hormonal antitumor treatment within one week prior to treatment start.
- •Symptomatic CNS metastases
研究者
相似试验
已完成
2 期
Trastuzumab-emtansine and osimertinib combination treatment to target HER2 bypass track resistance in EGFR mutation positive NSCLClung cancernon-small cell lung cancerNL-OMON55787Antoni van Leeuwenhoek Ziekenhuis58
进行中（未招募）
1 期
Activity of trastuzumab based chemotherapy in metastatic breast patients with HER2-negative primary tumor but HER2 positive circulating tumor cells (CareMore-Trastuzumab)EUCTR2014-004432-18-NLErasmus MC Cancer Institute37
已完成
2 期
A phase II study of obinutuzumab monotherapy in rituximab-refractory follicular lymphomafollicular lymphoma10025320lymphomaNL-OMON41828Vrije Universiteit Medisch Centrum6
已完成
2 期
[89Zr]trastuzumab PET/CT imaging of HER2 positive breast cancer for predicting pathologic complete response after neoadjuvant chemotherapy; a multicentre study10006232Breast cancerNL-OMON50044eids Universitair Medisch Centrum7
Unknown
2 期
Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive SystemTargeted TherapyHER2Biliary Tract CancerEsophageal Squamous Cell CarcinomaColorectal CancerNCT03185988Shen Lin100